# Fovea Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fovea-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Paris, France
- Website: www.fovea-pharma.com
- Total disclosed funding: $69M
- Latest round: Series B (Dec 12, 2007)
- Investors on record: 7

## About

Fovea Pharmaceuticals SA is a Paris-based biopharmaceutical company focused on developing and commercializing innovative therapies for unmet medical needs, particularly in niche disease areas.Founded in 2005 in Paris, France, Fovea Pharmaceuticals SA specializes in pharmaceuticals targeting specific medical conditions. The company underwent a significant transition in 2009 when it was acquired by Sanofi-Aventis for EUR 370 million, consolidating its position in the industry. The company has completed three notable deals, with its most recent occurring on October 1, 2009.Fovea Pharma specializes in the development and commercialization of innovative pharmaceutical products aimed at treating various medical conditions. Their core offerings include targeted therapeutics designed to address unmet medical needs in specific disease areas. The company's product portfolio focuses on enhancing patient outcomes through advanced formulations and delivery mechanisms, ensuring efficacy and safety for end users. Fovea Pharma primarily serves healthcare providers, hospitals, and specialty pharmacies, providing them with access to cutting-edge treatments. Their products are marketed in various geographical regions, including North America, Europe, and select markets in Asia, underscoring their commitment to expanding global access to their therapeutic solutions.Fovea Pharma generates revenue through a structured model that encompasses partnerships, direct-to-consumer sales, and collaborations with healthcare providers. The company engages in contract agreements with hospitals and specialty pharmacies, facilitating the distribution of its flagship products to end users. Transaction structures are designed to support both B2B and B2C sales, allowing for a flexible approach in reaching various customer segments. Fovea Pharma’s pricing strategies are aligned with industry standards, ensuring competitive positioning while providing value to its clients. The revenue is driven by the adoption of their trademarked products, reflecting the company's focus on delivering high-quality therapeutic options to the market.Fovea Pharmaceuticals plans to leverage its recent acquisition by Sanofi-Aventis to expand its product offerings and explore new markets. The company aims to introduce new therapies designed to treat niche diseases, with specific timelines for launch expected to be announced in the coming years. Additionally, Fovea is targeting expansion into emerging markets in Asia and Latin America by 2012, which will be supported by the recent funding received through its acquisition. The strategic focus will be on enhancing its product pipeline and increasing market penetration in these regions, ensuring better access to its therapeutic solutions.

## Funding rounds

- Series B, Dec 12, 2007, $44M — Abingworth, Sofinnova Partners, Wellcome Trust, Gimv, Omnes Capital, Forbion, Vesalius Biocapital
- Series A, Nov 7, 2005, $25M — Abingworth, Sofinnova Partners, Wellcome Trust, Gimv, Omnes Capital

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Wellcome Trust — Series A, Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A, Series B
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series B